These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Mechanism of action of ketamine. Stahl SM CNS Spectr; 2013 Aug; 18(4):171-4. PubMed ID: 23866089 [TBL] [Abstract][Full Text] [Related]
27. Riluzole Serum Concentration in Pediatric Patients Treated for Obsessive-Compulsive Disorder. Grant P; Farmer C; Song J; Kish T; Swedo S J Clin Psychopharmacol; 2017 Dec; 37(6):713-716. PubMed ID: 29045303 [TBL] [Abstract][Full Text] [Related]
28. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. Grant P; Song JY; Swedo SE J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):309-15. PubMed ID: 20807069 [TBL] [Abstract][Full Text] [Related]
30. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. Adams TG; Bloch MH; Pittenger C J Clin Psychopharmacol; 2017 Apr; 37(2):269-271. PubMed ID: 28121735 [No Abstract] [Full Text] [Related]
31. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Feusner JD; Kerwin L; Saxena S; Bystritsky A Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653 [TBL] [Abstract][Full Text] [Related]
32. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. Uzun O J Psychopharmacol; 2010 Mar; 24(3):425-7. PubMed ID: 19010977 [TBL] [Abstract][Full Text] [Related]
33. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate. Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029 [TBL] [Abstract][Full Text] [Related]
34. Prolonged exposure to ketamine increases brain derived neurotrophic factor levels in developing rat brains. Ibla JC; Hayashi H; Bajic D; Soriano SG Curr Drug Saf; 2009 Jan; 4(1):11-6. PubMed ID: 19149520 [TBL] [Abstract][Full Text] [Related]
35. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Zhou W; Wang N; Yang C; Li XM; Zhou ZQ; Yang JJ Eur Psychiatry; 2014 Sep; 29(7):419-23. PubMed ID: 24321772 [TBL] [Abstract][Full Text] [Related]
36. The Effect of Repeated Ketamine Infusion Over Facial Emotion Recognition in Treatment-Resistant Depression: A Preliminary Report. Shiroma PR; Albott CS; Johns B; Thuras P; Wels J; Lim KO J Neuropsychiatry Clin Neurosci; 2015; 27(4):362-4. PubMed ID: 25658683 [TBL] [Abstract][Full Text] [Related]
37. Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder: A Pilot Study. Linkovski O; Wheaton MG; Zwerling J; Odgerel Z; van Roessel P; Filippou-Frye M; Lombardi A; Wright B; Steinman SA; Simpson HB; Lee F; Rodriguez CI J Clin Psychopharmacol; 2019; 39(1):91-93. PubMed ID: 30531475 [No Abstract] [Full Text] [Related]
38. Ketamine as an antidepresessant: a brief research history. Wanderer JP; Rathmell JP Anesthesiology; 2014 Jul; 121(1):A29. PubMed ID: 24936933 [No Abstract] [Full Text] [Related]